[{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Kazia Therapeutics \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Paxalisib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ Kazia","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Kazia"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"ONC-201","moa":"Dopamine","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Kazia Therapeutics \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantrixil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Kazia Therapeutics \/ Oasmia","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Oasmia"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"EVT801","moa":"VEGFR 3","graph1":"Oncology","graph2":"Preclinical","graph3":"Kazia Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Kazia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Kazia Therapeutics \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"EVT801","moa":"VEGFR 3","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"EVT801","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"EVT801","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"QIMR Berghofer Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Paxalisib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paxalisib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paxalisib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"EVT801","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paxalisib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"QIMR Berghofer Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Paxalisib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute","highestDevelopmentStatusID":"12","companyTruncated":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute"}]

Find Clinical Drug Pipeline Developments & Deals by Kazia Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Kazia receives an exclusive, worldwide, licence for the development of any drugs, including GDC-0084 (paxalisib) within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 12, 2024

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : QIMR Berghofer Medical Research Institute

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : GDC-0084 (paxalisib) is a PI3K/mTOR inhibitor small molecule drug candidate, which is being evaluated for the treatment of newly diagnosed glioblastoma.

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 10, 2024

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : EVT801 is a highly selective small molecule VEGFR3 tyrosine kinase inhibitor targeting tumour angiogenesis. It is being evaluated for the treatment of advanced solid tumours in adults.

                          Brand Name : EVT801

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 01, 2024

                          Lead Product(s) : EVT801

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : GDC-0084 (paxalisib) is an oral PI3K/mTOR dual inhibitor, which is being evaluated for the treatment of patients with PI3K pathway mutation brain metastases.

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 21, 2024

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : GDC-0084 (paxalisib) is a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 06, 2023

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : GDC-0084 (paxalisib), a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, is being developed to treat multiple forms of brain cancer. The direct anti-cancer effects of PI3K inhibitors are well demonstrated, and five therapies have been approved by ...

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 15, 2022

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : QIMR Berghofer Medical Research Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : EVT801 is an inhibitor of vascular endothelial growth factor receptors (VEGFR), which play an important role in angiogenesis and lymphangiogenesis (processes that contribute to tumor growth and metastasis), making VEGFR a well-established therapeutic tar...

                          Brand Name : EVT801

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 09, 2022

                          Lead Product(s) : EVT801

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Evotec

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : EVT801, a small-molecule, is a selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 was confirmed in preclinical studies to be a potent and selective inhibitor of VEGFR3, with activity in the low nanomolar range.

                          Brand Name : EVT801

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 01, 2022

                          Lead Product(s) : EVT801

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The safety profile of paxalisib in combination was broadly consistent with monotherapy experience in other clinical trials, and a maximum tolerated dose (MTD) of 45mg daily in combination with radiotherapy was confirmed.

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 05, 2022

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : GDC-0084 (paxalisib), a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 01, 2022

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Global Coalition for Adaptive Research

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank